company background image
EOLS logo

Evolus NasdaqGM:EOLS Stock Report

Last Price

US$14.42

Market Cap

US$839.8m

7D

10.3%

1Y

59.3%

Updated

28 Feb, 2024

Data

Company Financials +

EOLS Stock Overview

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.

EOLS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Evolus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evolus
Historical stock prices
Current Share PriceUS$14.42
52 Week HighUS$14.82
52 Week LowUS$7.07
Beta1.5
1 Month Change7.05%
3 Month Change52.27%
1 Year Change59.34%
3 Year Change4.80%
5 Year Change-41.26%
Change since IPO25.39%

Recent News & Updates

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Evolus (NASDAQ:EOLS) Has Debt But No Earnings; Should You Worry?

Sep 11
Evolus (NASDAQ:EOLS) Has Debt But No Earnings; Should You Worry?

Revisiting Evolus

Sep 09

Evolus (NASDAQ:EOLS) Is Carrying A Fair Bit Of Debt

Mar 03
Evolus (NASDAQ:EOLS) Is Carrying A Fair Bit Of Debt

Shareholder Returns

EOLSUS PharmaceuticalsUS Market
7D10.3%1.0%1.8%
1Y59.3%25.7%25.6%

Return vs Industry: EOLS exceeded the US Pharmaceuticals industry which returned 26.1% over the past year.

Return vs Market: EOLS exceeded the US Market which returned 26% over the past year.

Price Volatility

Is EOLS's price volatile compared to industry and market?
EOLS volatility
EOLS Average Weekly Movement8.1%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: EOLS's share price has been volatile over the past 3 months.

Volatility Over Time: EOLS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012246David Moatazedihttps://www.evolus.com

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market.

Evolus, Inc. Fundamentals Summary

How do Evolus's earnings and revenue compare to its market cap?
EOLS fundamental statistics
Market capUS$839.84m
Earnings (TTM)-US$63.02m
Revenue (TTM)US$184.73m

4.5x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EOLS income statement (TTM)
RevenueUS$184.73m
Cost of RevenueUS$55.66m
Gross ProfitUS$129.07m
Other ExpensesUS$192.09m
Earnings-US$63.02m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 07, 2024

Earnings per share (EPS)-1.09
Gross Margin69.87%
Net Profit Margin-34.11%
Debt/Equity Ratio-491.0%

How did EOLS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.